Alexa
  • Directory of Taiwan

EU approves hepatitis treatment, triggering payment by Novartis

EU approves hepatitis treatment, triggering payment by Novartis

The European Commission on Monday approved Sebivo, a once-a-day oral treatment for adult patients with chronic hepatitis B and liver disease.
The approval of the drug in Europe triggers a milestone payment from Novartis Pharma AG to Cambridge, Massachusetts-based Idenix Pharmaceuticals Inc. The company did not say how much the payment would be.
The commission's decision applies to all 27 countries in the European Union as well as Iceland and Norway. Launches are expected to start in the second quarter of 2007 beginning with the U.K. and Germany.
Idenix and Novartis Pharma AG are co-promoting the drug and other possible hepatitis treatments under a May 2003 agreement. Under that deal Novartis and Idenix will cooperate on the drugs in the United States, France, Germany, Italy, Spain and the United Kingdom, while Novartis will have exclusive rights in the rest of the world.
In addition to the European Union, Sebivo is currently approved in more than 15 major markets, including the U.S. where it is marketed as Tyzeka, Canada, Switzerland and China.


Updated : 2021-06-18 05:48 GMT+08:00